276) A 70 year old obese woman is evaluated in your office during an annual follow up visit. Her other medical problems include hypertension, chronic sinusitis, nasal polyps, asthma, osteoarthritis and a history of transient ischemic attack about 2 months ago. She uses acetaminophen for her arthritis pain because ibuprofen makes her “swell up” and causes severe “breathing problems”. Upon review of her medications, you note that she is not on any antiplatelet therapy. Physical examination is unremarkable except for nasal polyps. Which of the following recommendations is most appropriate management for this patient?
A) Warfarin
B) Aspirin and Dipyridamole
C) Aspirin
D) Clopidogrel
E) Dipyridamole
F) No anti-platelet therapy
Filed under: Uncategorized, USMLE Test Prep | Tagged: archer neurology, archer preventive medicine, neurology mcqs, neurology usmle mcqs, stroke prevention, usmle step 3 neurology, usmle step 3 preventive medicine |
Archer USMLE Step 3 Blog 
D
D. Patients with allergies to ibuprofen (NSAIDs) will also have allergies to aspirin. Patient has a history of MI, so antiplatelet RX has been shown to reduce mortality. Next best choice for antiplatelet RX would be clopidogrel.
D- Clopidogrel
This patient has what is called “triad asthma”,this is: asthma,ASA sensitivity, nasal polyps with chronic sinusitis
D
D…….. Antiplatelet therapy is a mainstay of secondary prevention of ischemic strokes. Recent studies, such as Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS), the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial, and the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), have added much to our understanding about how best to utilize the various antiplatelet agents available. Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone. Recently, clopidogrel was demonstrated to be “noninferior” to an aspirin/dipyridamole combination, and can be considered as a first-line agent.